CompletedNot Applicable

Serum Magnesium Concentration in Magnesium Sulfate Therapy for Severe Preeclampsia

Vietnam64 participantsStarted 2022-03-15

Plain-language summary

Pregnant women diagnosed with pre-eclampsia with severe features will be treated with magnesium sulfate to prevent seizures. Magnesium sulfate will be administered according to My Duc Hospital's protocol for treatment of pre-eclampsia (a loading dose of 4.5g given intravenously in 20 min, followed by a maintenance dose at an infusion rate of 1.5g/h). Serum magnesium concentrations will be measured before the loading dose and 0.5h, 1h, 2h, and every 6 hours thereafter.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant women * Aged ≥ 18 * Diagnosed with pre-eclampsia with severe features, with or without chronic hypertension, as defined by the American College of Obstetricians and Gynecologists (ACOG) diagnosis criteria. * Provision of written informed consent to participate as shown by a signature on the patient consent form. Exclusion Criteria: * Impaired renal function (eGFR \< 60 mL/min/ 1,73 m2 or oliguria ) * Occurrence of eclampsia before magnesium sulfate administration * Known hypersensitivity to the drug, * Severe myasthenia, atrioventricular block * A diminished level of consciousness.

What they're measuring

Serum magnesium concentrations before and during magnesium sulfate infusion

Timeframe: From administration of loading dose until termination of magnesium sulfate treatment or occurrence of magnesium toxicity, whichever comes first, approximately up to 36 hours.

Trial details

NCT IDNCT05283473

SponsorMỹ Đức Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-02-21

View on ClinicalTrials.gov More Severe Pre-Eclampsia trials